Company news

Imagion Biosystems Ltd. news in 2023

Imagion Biosystems Ltd.'s news releases, calls and decks from 2023, newest first.

View company

Imagion Announces Positive Results from Phase 1 Study

December 6, 2023

Phase 1 Study Closure and Preliminary Performance

October 17, 2023

Notice of Extraordinary General Meeting/Proxy Form

October 12, 2023

Imagion presents ovarian cancer data at AACR conference

October 8, 2023

2022 R&D Tax Refund

September 18, 2023

Appendix 4D

August 29, 2023

Half-Year Results Release

August 29, 2023

Non-renounceable Entitlement Offer Shortfall

July 14, 2023

Imagion to complete the MagSense HER2 Phase 1 Study

June 20, 2023

Imagion Announces New CEO

June 18, 2023

Results of Non-renounceable Entitlement Offer

April 18, 2023

Imagion Funding Update

March 6, 2023

Non-renounceable Entitlement Offer

March 6, 2023

Imagion Secures Growth Funding

March 6, 2023

Appendix 4E

February 27, 2023

Company Update - Phase 1 Study Independent Review

February 5, 2023

Decks in 2023